knowledge -WSS

knowledge

author：comprehensive 2025-09-03 03:29:36 - browse：8936

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： A solution to the after

focus

WSS

Wegovy, Zepbound and weight loss drugs that preserve muscle

Childhood cancer progress stalls for Black, Hispanic kids: Report

Anthos stroke drug appears safer than common blood thinner

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Surge of respiratory disease in China has likely explanation

Wegovy, Zepbound and weight loss drugs that preserve muscle

Wikipedia

knowledge

entertainment

In age of alternative facts, a scholarly course on calling out crap

Gain of function research would be limited under House proposal

Sports medicine is finally prioritizing gender equality

Poor hospice wound care hurts patients and families

United colonoscopy coverage change 'may cost lives,' doctors say

A solution to the after

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

NIH study of ME/CFS points to clear biological hallmarks

hotspot

PBM reform efforts get punted in Congress

A new nitrogen execution bill also undermines medical licensing

With competition flaring, obesity drug hits goal in liver disease study

Antivenom research: Lessons from HIV applied in search for universal antidote

Surge of respiratory disease in China has likely explanation

Alabama hospital puts IVF treatments on hold

explore

leisure time

focus

hotspot